Living with Diabetes? Check out our site for you

Healthcare professional? This is your dedicated site.




Multiple Daily Injections (MDI) is typically the first line of treatment in Australia and is defined as the administration of three or more insulin injections per day. This includes one injection of long-acting insulin in the evening and an injection of rapid or short-acting insulin before each meal.

Long-acting insulins do not have a pronounced peak effect as they are designed to replace physiologic basal insulin secretion. They are designed to dissipate slowly and evenly into the bloodstream for approximately 24 hours following administration.

On this regimen, the physiologic replacement of mealtime insulin secretion is administered three times a day using rapid or short-acting insulin. These injections are given before meals and are typically adjusted to match food intake using an insulin-to-carbohydrate ratio. 

When compared to regular insulin, rapid-acting insulin is typically preferred because it provides better physiologic insulin coverage for meals and more closely matches the glucose rise that occurs in response to meals. The peak action time of rapid-acting insulin occurs at approximately 1-1.5 hours after administration. This correlates well with the digestive time of most meals.

iPro2 provides more accurate data

There are times when, using the fingerstick method, you may miss your patients’ hypos or hypers, as seen in the graph above.  Fingersticks can only tell you so much. By using iPro2, the only available professional CGM designed for the masked collection of glucose data, you will enjoy more precise insights into your patients’ glycaemic profile.


Alternatives to MDI

MiniMedTM 670G provides better control

When it comes to diabetes, none of us are exactly alike. What we do, what we eat, and even how our bodies react to insulin affect our blood glucose in completely different ways.

The MiniMedTM 670G system is the world’s first self-adjusting insulin pump system1. Powered by SmartGuardTM Auto Mode technology, it automatically adjusts basal insulin delivery every five minutes, based on continuous glucose monitoring (CGM) readings. It personalises diabetes management, helping to stabilise glucose levels for maximum protection from highs and lows The breakthrough MiniMed® 670G pump and continuous glucose monitoring (CGM) system is the first and only system1 that constantly self-adjusts based on how patients live every day.


  • Even though long acting insulins are designed to last 24 hours without a pronounced peak, it does not last this long in many individuals, and in others may last longer
  • Some patients must divide their long acting insulin into two injections, with half of the dose administered in the morning and the other half administered in the evening
  • The acidic pH of long acting insulin can result in a slight burning sensation when it is administered.

i-Port Advance offers a life with fewer injections 
Do you have patients who miss their regular injections because of needle phobia? i-Port Advance is a new injection port designed to overcome the pain and anxiety associated with injections.


^Components sold separately. Automated insulin delivery is made possible through combining Medtronic insulin pump and continuous glucose monitoring technology.